Described herein is a method for forming multi-layer drug dosage forms having at least two layers. In the method, a first formulation comprising a non-gelling matrix forming agent and having a first density is dosed into a preformed mold. A second formulation comprising a non-gelling matrix former and having a second density not equal to the first density is subsequently dosed into the preformed mold. Then, the combination of the formulations dosed into the mold is freeze dried to form the multi-layer dosage form having at least two layers. The use of a density difference between the first and second formulations ensures formation of a product with two distinct layers.

The invention relates to a nicotine oral delivery product containing a powder enclosed in a water insoluble pouch, wherein said pouch is permeable for saliva and therein dissolved parts of the powder, wherein said powder comprising at least a) nicotine selected from the group consisting of tobacco, nicotine salts, nicotine base, stabilized nicotine, and mixtures thereof corresponding to 0.1 to 20 mg nicotine in the form of nicotine base and b) a chewing gum composition and a method of producing said nicotine oral delivery product.

The present invention relates to a liquid pharmaceutical composition comprising cytisine, at least one inorganic pH-regulating agent selected from the group consisting of inorganic acids, inorganic buffers, and inorganic acid salts, and water, wherein the liquid pharmaceutical composition has a pH value between 3.0 and 7.5. The present invention furthermore relates to the liquid harmaceutical composition for use in the treatment of tobacco smoking addiction and other forms of nicotine addiction. Additionally, the invention relates to a liquid pharmaceutical composition comprising cytisine for oral use in the treatment of tobacco smoking addiction and other forms of nicotine addiction.

This invention relates to a nicotine lozenge giving an immediate release and uptake of nicotine and an extended release and uptake of nicotine as well as describing suitable manufacturing processes for such lozenge formulations and the use of the lozenge for the treatment of a human being suffering from cravings from tobacco and/or e-cigarette dependency.

Cannabidiol derivatives and medical use thereof, in particular to the compounds represented by general formula (I), or stereoisomers, solvates, metabolites, prodrugs, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of substituents in general formula (I) are the same as those in the description

##STR00001##

An earplug (1) for administering a fluid agent into an ear canal is provided. The earplug (1) comprises a first part (10) adapted for insertion in the ear canal. The first part comprises an elongated member (11) having a chamber (12) for containing the fluid agent, the chamber (12) having at least one outlet (13) at a proximal end (14) of the elongated member (11); and a malleable member (17) disposed laterally of the elongated member (11). The earplug (1) further comprises a second part (20) comprising a piston (21). The piston (21) has a first end (22) which is insertable in the elongated member (11), and a second end (23) which has a push member (24). The piston (21) is displaceable from a first position (A) distally of the chamber (12) to a second position (B) within the chamber (12), such that the fluid agent is injected from the chamber (12) through the outlet (13) into the ear canal.

Provided are compositions and methods comprising a sanshool for the treatment of obesity as part of a controlled diet regime in an individual. Also provided are compositions and methods comprising a sanshool for treatment of a smoking or vaping addiction. Suitably the compositions are applied topically to the lips of the individual in response to a habitual urge to consume food, smoke or vape as required.

Provided are compositions and methods comprising a sanshool for the treatment of obesity as part of a controlled diet regime in an individual. Also provided are compositions and methods comprising a sanshool for treatment of a smoking or vaping addiction. Suitably the compositions are applied topically to the lips of the individual in response to a habitual urge to consume food, smoke or vape as required.

Compounds and berberine compositions containing such compounds that are useful for reducing nicotine dependency. Methods for administering the berberine compositions are also disclosed. The compounds may have a structure according to Formula (I). In Formula (I) R1, R2, R3, R4, and R5 are independently H or D; R6 and R7 are independently hydrogen, deuterium, halogen, C4 to C8 unsubstituted aryl, C4 to C8 substituted aryl, C2 to C6 unsubstituted heterocycle, C2 to C6 substituted heterocycle, C1 to C6 unsubstituted alkyl, C1 to C6 substituted alkyl, C3-C10 unsubstituted cycloalkyl, C3-C10 substituted cycloalkyl, or R6 and R7 are taken together as ═O or ═S; and R8 and R9 are independently selected from a group consisting of methyl, CHF2, and CF3.

Compounds and berberine compositions containing such compounds that are useful for reducing nicotine dependency. Methods for administering the berberine compositions are also disclosed. The compounds may have a structure according to Formula (I). In Formula (I) R1, R2, R3, R4, and R5 are independently H or D; R6 and R7 are independently hydrogen, deuterium, halogen, C4 to C8 unsubstituted aryl, C4 to C8 substituted aryl, C2 to C6 unsubstituted heterocycle, C2 to C6 substituted heterocycle, C1 to C6 unsubstituted alkyl, C1 to C6 substituted alkyl, C3-C10 unsubstituted cycloalkyl, C3-C10 substituted cycloalkyl, or R6 and R7 are taken together as ═O or ═S; and R8 and R9 are independently selected from a group consisting of methyl, CHF2, and CF3.